SRSF2 Mutation Cooperates with ASXL1 Truncated Alteration to Accelerate Leukemogenesis
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Distinct clinical profiles and patient outcomes in aCML and CNL.
Sun Y, Wang Q, Zhang Z, Wang Q, Cen J, Zhu M Ann Hematol. 2024; 103(12):5325-5332.
PMID: 39375227 DOI: 10.1007/s00277-024-06032-z.
References
1.
Kim E, Ilagan J, Liang Y, Daubner G, Lee S, Ramakrishnan A
. SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. Cancer Cell. 2015; 27(5):617-30.
PMC: 4429920.
DOI: 10.1016/j.ccell.2015.04.006.
View
2.
Thol F, Friesen I, Damm F, Yun H, Weissinger E, Krauter J
. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol. 2011; 29(18):2499-506.
DOI: 10.1200/JCO.2010.33.4938.
View
3.
Patel J, Gonen M, Figueroa M, Fernandez H, Sun Z, Racevskis J
. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366(12):1079-89.
PMC: 3545649.
DOI: 10.1056/NEJMoa1112304.
View
4.
Stieglitz E, Taylor-Weiner A, Chang T, Gelston L, Wang Y, Mazor T
. The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2015; 47(11):1326-1333.
PMC: 4626387.
DOI: 10.1038/ng.3400.
View
5.
Brecqueville M, Rey J, Bertucci F, Coppin E, Finetti P, Carbuccia N
. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer. 2012; 51(8):743-55.
DOI: 10.1002/gcc.21960.
View